Healthcapital SA is participating as co-investor in investment syndicates. Per life cycle of investment in a company, our investment size is on average $25m in aggregate.
Healthcapital SA typically addresses initial investments in private companies whose innovative primary products are in clinical development or the immediately preceding stage. Optimal investment opportunities will have some proof of efficacy in humans prior to the investment.
- Biopharmaceutical Companies with proprietary compounds or products thathave the potential to become new therapeutics.While we will consider any exciting biotech. investment opportunity, weparticularly focus on ONC, CNS, TX, immunology, virology, ID, CVS, metabolic diseases, from chemical to biologic compounds.
- Product Platform Companies that use proprietary technologies to discover new drug candidates for internal development and/or partnerships.
- Medtech Companies with cardiovascular, respiratory, and kidney approaches.